Stella M. Davies, MBBS, PhD, MRCP
- Director, Division of Bone Marrow Transplantation and Immune Deficiency
- Institute Co-Executive Director, Cancer and Blood Diseases Institute
- Jacob G. Schmidlapp Endowed Chair
- Professor, UC Department of Pediatrics
About
Biography
As a doctor specializing in bone marrow transplantation, I enjoy forming long-term relationships with patients and their families and traveling with them on their journey.
Everyone’s path is different, and our team of doctors and nurses is committed to exceptional care. We deliver personalized treatments to each child and adolescent — one size fits no one!
I am honored to be president-elect of the American Society of Transplantation and Cellular Therapy, the professional society for bone marrow transplant specialists.
In my research, my colleagues and I focus on finding out what causes complications after bone marrow transplantation and determine better ways to fix these complications.
In my spare time, I enjoy supporting my daughter, a Cincinnati Rollergirl, at roller derby bouts.
MBBS: University of Newcastle-Upon-Tyne, Newcastle upon Tyne, England, 1981
Clinical And Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1985
PhD: University of Newcastle-Upon-Tyne, Newcastle-Upon-Tyne, England, 1989
Fellowship: University of Minnesota, Minneapolis, MN, 1993
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Childhood cancer etiology: recent reports. Pediatric Blood and Cancer. 2003; 40(1):35-38.
Is it possible to catch leukaemia from a cat? The Lancet. 1994; 344(8936):1580.
Epidemiology of childhood leukemia, with a focus on infants. Epidemiologic Reviews. 1994; 16(2):243-272.
Maintenance of genomic imprinting at the IGF2 locus in hepatoblastoma. Cancer Research. 1993; 53(20):4781-4783.
Bone marrow transplant for acute leukaemia. Best Practice and Research: Clinical Haematology. 1991; 4(2):483-510.
TA-TMA and GVHD are distinct consequences of endothelial injury: A MIDAS consortium study. Blood advances. 2026.
Breaking Access Barriers to Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy in Hematologic Malignancies-an ASTCT-NMDP ACCESS Initiative. Transplantation and Cellular Therapy. 2026; 32(6):737-753.
Plasma proteomics and single-cell RNA-seq identify cellular and soluble mechanisms of graft rejection after HSCT. Blood Immunology & Cellular Therapy. 2026; 2(2):100046.
The gut virome in children undergoing hematopoietic cell transplantation is diverse and a site for viral reactivation. Bone Marrow Transplantation. 2026.
Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT. Transplantation and Cellular Therapy. 2026.
From the Blog
Clinical Trial to Evaluate Safer CAR T-Cell Therapy for Children
Stella M. Davies, MBBS, PhD, MRCP4/14/2026
Vitamin A May Reduce CVHD Risk After Stem Cell Transplantation
Stella M. Davies, MBBS, PhD, MRCP, Pooja Khandelwal, MD3/21/2024
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey